The prognostic significance of epithelial-mesenchymal transition in breast cancer

Anticancer Research

Volumn 22, Issue 6 A, 2002, Pages 3415-3419

  Fuchs, Ilka B ^a   Lichtenneger, Werner ^a   Buehler, Helmut ^a   Henrich, Wolfgang ^a   Stein, Harald ^a   Kleine Tebbe, Anke ^a   Schaller, Gerhard ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Breast cancer; Keratin; Prognosis; Vimentin

Indexed keywords

CYTOKERATIN 19; KERATIN; VIMENTIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CORRELATION ANALYSIS; EPITHELIUM CELL; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MESENCHYME CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-8; KERATINS; MESODERM; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SURVIVAL RATE; TUMOR CELLS, CULTURED; VIMENTIN;

EID: 0036870658     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Valles AM, Boyer B, Badet J, Tucker GC, Barribault D and Thiery. JP: Acidic fibroblast growth factor is a modulator of epithelial plasticity in a rat bladder carcinoma cell line. Proc Natl Acad Sci USA 87: 1124-1128, 1990.
2. Boyer B, Tucker GC, Vallés AM, Francke WW and Thiery JP: Rearrangement of desmosomal and cytoskeletal proteins during the transition from epithelial to fibroblastoid organisation in cultured rat bladder carcinoma cells. J Cell Biol 109: 1495-1509, 1989.
3. Moll R: Cytokeratins as Markers of Differentiation: Expression Profiles in Epithelial Tumours. Gustav Fischer Stuttgart, 1993.
4. Eichner R, Sun T-T and Aebi U: The role of keratin subfamilies and keratin pairs in the formation of human epidermal intermediate filaments. J Cell Biol 102: 1767-1777, 1986.
5. Hatzfeld M and Franke WW: Pair formation and promiscuity of cytokeratins: formation in vitro of heterotypic complexes and intermediate-sized filaments by homologous and heterologous recombinations of purified polypeptides. J Cell Biol 101: 1826-1841, 1985.
6. Galou M, Gao J, Humbert J, Mericskay M, Li Z, Paulin D and Vicart P: The importance of intermediate filaments in the adaptation of tissues to mechanical stress, evidence from gene knockout studies. Biol Cell 89: 85-89, 1997.
7. Schaller G, Fuchs 1, Pritze W, Ebert A, Herbst H, Pantel K, Weitzel H and Lengyel E: Elevated keratin 18 protein expression indicates a favourable prognosis in patients with breast cancer. Clin Cancer Res 2: 1879-1885, 1996.
8. Cordell JL, Falini B, Erber W, Ghosh, AK, Abdulaziz Z, MacDonald S, Pulford KAF, Stein H and Mason DY: Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAA-P complexes). J Histochem Cytochem 32: 219-229, 1984.
9. Remmele W and Stegner HE: Immunhistochemischer nachweis von östrogenrezeptoren (Er-ICA) im mammakarzinomgewebe, vorschlag zur einheitlichen bewertung des untersuchungsbefundes. Der Frauenarzt 2: 41-43, 1987.
10. Takei H, Iino Y, Horiguchi J, Kanoh T, Takao Y, Oyama T and Morishlta Y: Immunohistochemical analysis of cytokeratin 8 as a prognostic factor in invasive breast carcinoma. Anticancer Res 15: 1101-1105, 1995.
11. 1Franzen B, Linder S, Alaiya AA, Eriksson E, Uruy K, Hirano T, Okuzawa K and Auer G: Analysis of polypeptide expression in benign and malignant human breast lesions: down regulation of cytokeratins. Br J Cancer 73: 1632-1638, 1996.
12. Pankov R. Simcha 1, Zöller M, Oshima RG and Ben-Ze'ev A: Contrasting effects of K8 and K18 on stabilizing K19 expression, cell motility and tumorigenicity in the BSp73 adenocarcinoma. J Cell Sci 110: 965-974, 1997.
13. Bartek J, Taylor-Papadimitrlou J, Miller N and Millis R: Patterns of expression of keratin 19 as detected with monoclonal antibodies in human breast tissues and tumours. Int J Cancer 36: 299-306, 1985.
14. Stasiak PC, Purkis PE, Leigh IM and Lane EB: Keratin 19: predicted amino acid sequence and broad tissue distribution suggest it evolved from keratinocyte keratins. J Invest Dermatol 92: 707-716, 1989.
15. Wada T, Yasutomi M, Hashimura K, Kunikata M, Tanaka T and Mori M: Vimentin expression in benign and malignant lesions in the human mammary gland. Anticancer Res 12: 1973-1982, 1992.
16. Thompson EW, Soonmyoung P, Briinner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S, Lippman ME, Martin GR and Dickson RB: Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 150: 534-544, 1992.
17. Sommers CL, Byers SW, Thompson EW, Torri JA and Gelmann EP: Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res Treat 31: 325-335, 1994.
18. Domagala W, Lasota J, Bartkowiak J, Weber K, and Osborn M: Vimentin is preferentially expressed in human breast carcinoma with low estrogen receptor and high Ki-67 growth fraction. Am J Pathol 136: 219-227, 1990.
19. Hu XC and Chow LW: Detection of circulating breast cancer cells with multiple-marker RT-PCR assay. Anticancer Res 21: 421-424, 2001.
20. Wingren S, Stal O, Sullivan S, Brisfors A and Nordenskjold B: S-phase determination of immunoselected cytokeratin-containing breast cancer cells improves the prediction of recurrence. Breast Cancer Res Treat 29: 179-187, 1994.
21. Ferrero M, Spyratos F, LeDoussal V, Desplaces A and Rouesse J: Flow cytometric analysis of DNA content and keratins by using CK7, CK8, CK18, CK19 and KLI monoclonal antibodies in benign and malignant human breast tumors. Cytometry 11: 716-724, 1990.
22. Vannucchi AM, Bosi A, Glinz S, Pacini P, Linari S, Saccardi R, Alterini R, Ridacci L, Guidi S, Lombardini L, Longo G, Mariani MP and Rossi-Feffini P: Evaluation of breast tumor cell contamination in the bone marrow and leukapheresis collections by RT-PCR for cytokeratin 19 mRNA. Br J Haematol 103: 610-617, 1998.
23. Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, Funke I, Izbicki JR and Riethmfiller G: Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 85: 1419-1424, 1993.
24. Shammas FV, Deak E, Nysted A, van Eekelen JA, Osland A and Heikkila R: Serial quantitative PCR analysis of bone marrow samples from breast cancer patients to monitor systemic micrometastases. Anticancer Res 21: 2099-106, 2001.
25. Early Breast Cancer Trialist' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, of immune therapy, 133 randomised trials involving 31, 000 recurrences and 24,000 deaths among 75,000 women. Lancet 339: 71-85, 1992.